Date	Trial Summary	Phase	Inclusion Criteria	Locations	Sponsors	Identifier- LINK	Comments
Recruiting for 1st or 2nd+ Line Treatment (ALK TKI Treatment Naïve or Prior ALK TKIs)							
21/07/2022	Multi-modality local consolidative treatment (LCT) versus conventional care of advanced lung cancer after first line systemic anti-cancer treatment (RAMON)	III	Stage 4 ALK lung cancer (or other types) Currently prescribed TKI for a minimum of 3 months Able to have local treatment to all areas of residual disease	**UK:** London (Royal Brompton). Other sites in the UK planned.	NIHR	https://fundingawards.nihr.ac.uk/award/NIHR131306	Participants will be randomzed to have either LCT after starting a TKI, vs. TKI and standard treatment only.
Recruiting for ALK NSCLC 2nd-3rd-4th Line Treatment After One or More ALK TKIs							
11/27/2017	Stereotactic Body Radiotherapy for the Treatment of Oligo-Progressive Disease (HALT)	II/III	Advanced NSCLC with actionable mutation receiving TKI Confirmed oligo-progressive disease with 3 or fewer sites Sites of progression are suitable for treatment with SBRT	**UK**: Sutton, Chelsea, Guildford, Manchester, Nottingham, Sheffield	Institute of Cancer Research, United Kingdom	NCT03256981 -	Randomized to SBRT + TKI or indicated TKI alone. Not clear if still recruiting
12/11/2014	Alectinib: Deciphering anti tumor response and resistance with intratumor heterogenicity (Darwin II)	II	ALK/RET gene fusion relapsed disease Biopsy of relapsed disease Multi-region sequencing of the primary tumor available	**UK**: London - University College Hospital	University College, London Hoffman-La Roche	NCT02314481